|
“Miro” Study, a FIL multicenter phase II trial combining local radiotherapy and MRD-driven immunotherapy in early-stage follicular lymphoma. |
|
|
Consulting or Advisory Role - Merck; Pfizer; Roche; Sandoz; Takeda |
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Roche |
Travel, Accommodations, Expenses - Roche; Takeda |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - EUSA Pharma; Janssen-Cilag |
Speakers' Bureau - Gilead Sciences; Janssen-Cilag; SERVIER |
Research Funding - Gilead Sciences |
Travel, Accommodations, Expenses - EUSA Pharma; Gentili; Janssen-Cilag; Roche; Sanofi; SERVIER |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Incyte; SERVIER; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Kite/Gilead; SERVIER |
Research Funding - Celgene (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Gilead Sciences; MolMed; Roche; Takeda |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Italfarmaco; Janssen; Merck Sharp & Dohme; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Tolero Pharmaceuticals |
Travel, Accommodations, Expenses - Janssen; Roche |
|
|
No Relationships to Disclose |